Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 22:5:72.
doi: 10.1186/1746-1596-5-72.

Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study

Ehab S Abd-Elhamid  1 , Mohamed H Elmalahy
Affiliations

Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study

Ehab S Abd-Elhamid et al. Diagn Pathol. .

Abstract

Aims and objectives: This study aims to analyze immunocytochemically p53 aberrant expression and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma (MEC) of parotid gland and to ascertain if expression of these markers correlates with tumor behavior, clinical outcome, histological grade and local recurrence.

Methods: 20 cases histologically diagnosed as primary MEC with different grades were included in the study. Out of 20 cases, 7 were classified as grade I, 8 as grade II and 5 as grade III. Immunohistochemical staining of these 20 primary cases as well as 6 recurrent cases with anti-p53 and anti-mdm-2 antibodies was carried out. Area fraction of immunopositivity was estimated by image analysis software.

Results: 16/20 primary cases were p53 +ve (80%). The p53 positive cases included 3 cases classified as grade (I), 8 cases as grade (II) and 5 cases as grade (III). All 6 recurrent cases were p53 +ve. On the other hand, 14/20 primary and only 2/6 recurrent cases were mdm-2 +ve. The mdm-2 +ve primary cases included 2 classified as grade (I), 7 as grade (II) and 5 as grade (III). 12 primary MEC showed co-expression of both p53 and mdm-2 of which 2 cases showed local recurrence.

Conclusions: These data suggested that expression of p53 and mdm-2 in primary and recurrent MEC correlates with the high histological grade. P53 aberrant expression is not only considered as an early event in MEC carcinogenesis but also correlates to tumor behavior and local recurrence. Mdm-2 overexpression is correlated to pathogenesis of MEC. However, no strong evidence was found between mdm-2 expression and MEC local recurrence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Low grade MEC showing cystic spaces and duct-like structures lined by mucous-secreting cells together with few differentiated epidermoid cells (HE × 200).
Figure 2
Figure 2
Intermediate grade MEC showing tumor nests formed of epidermoid cells intermingled with clear mucous cells together with duct-like structures lined by both types of cells (HE × 200).
Figure 3
Figure 3
High grade MEC showing nests of epidermoid cells some of which are differentiated into epithelial pearls with central keratinization. Note the few scattered mucous-secreting cells (HE × 200).
Figure 4
Figure 4
Primary MEC showing positive nuclear immunostaining of epidermoid cells forming tumor nests. The mucous cells were immunonegative (Anti-p53 × 100).
Figure 5
Figure 5
Recurrent MEC showing positive nuclear immunostaining of epidermoid cells forming the advancing front of the tumor nests. The mucous cells were immunonegative (Anti-p53 × 100).
Figure 6
Figure 6
Primary MEC showing positive nuclear and cytoplasmic immunostaining of epidermoid cells forming tumor nests. The mucous cells were immunonegative (Anti-mdm-2 × 100).
Figure 7
Figure 7
Recurrent MEC showing positive nuclear and cytoplasmic immunostaining of epidermoid cells forming tumor nests. The mucous cells were immunonegative (Anti-mdm-2 × 100).
Figure 8
Figure 8
A scatter plot representing a linear positive correlation between p53 and mdm-2 expression in MEC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Matizonkas-Antonio LF, Mesquita RA, Machado de Souza SO, Nunes FD. TP53 mutations in salivary gland neoplasms. Braz Dent J. 2005;16(2):162–166. doi: 10.1590/S0103-64402005000200014. - DOI - PubMed
    1. Argawal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The P53 network. J Biol Chem. 1998;273:1–4. doi: 10.1074/jbc.273.1.1. - DOI - PubMed
    1. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med. 1993;329:1318–27. doi: 10.1056/NEJM199310283291807. - DOI - PubMed
    1. Chen L, Agarwal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci. 1998;95:195–200. doi: 10.1073/pnas.95.1.195. - DOI - PMC - PubMed
    1. Zhang Z, Li M, Wang H, Agarwal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. PNAS. 2003;100(20):11636–11641. doi: 10.1073/pnas.1934692100. - DOI - PMC - PubMed

MeSH terms